Overzicht belangen werkgroepleden
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
Regel 1: | Regel 1: | ||
{| width="100%" cellspacing="1" cellpadding="1" border="1" | {| width="100%" cellspacing="1" cellpadding="1" border="1" | ||
|- | |- | ||
- | | bgcolor="#cccccc" | '''Naam''' | + | | bgcolor="#cccccc" | '''Naam''' |
+ | |||
| bgcolor="#cccccc" | '''Firma''' | | bgcolor="#cccccc" | '''Firma''' | ||
| bgcolor="#cccccc" | | | bgcolor="#cccccc" | | ||
Regel 24: | Regel 25: | ||
| Viiv | | Viiv | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
| align="center" | x | | align="center" | x | ||
- | | align="center" | | + | | align="center" | <br> |
|- | |- | ||
- | | | + | | <br> |
| BMS | | BMS | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| MSD | | MSD | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Gilead | | Gilead | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
| align="center" | x | | align="center" | x | ||
- | | align="center" | | + | | align="center" | <br> |
|- | |- | ||
- | | | + | | <br> |
| Roche | | Roche | ||
- | | | + | | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Abbott | | Abbott | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Jansen-Tibotec | | Jansen-Tibotec | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
| align="center" | x | | align="center" | x | ||
- | | align="center" | | + | | align="center" | <br> |
|- | |- | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
| Mariska Tuut | | Mariska Tuut | ||
| Geen | | Geen | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
| Suzanne Geerlings | | Suzanne Geerlings | ||
| MSD | | MSD | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Viiv | | Viiv | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| BMS | | BMS | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Gilead | | Gilead | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
| align="center" | x | | align="center" | x | ||
| align="center" | Amsterdamdiner | | align="center" | Amsterdamdiner | ||
|- | |- | ||
- | | | + | | <br> |
| Abbott | | Abbott | ||
- | | align="center" | | + | | align="center" | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Jansen Cilag (Tibotec) | | Jansen Cilag (Tibotec) | ||
- | | | + | | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Boehringer Ingelheim<br> | | Boehringer Ingelheim<br> | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | align="center" | | + | | align="center" | <br> |
| align="center" | Amsterdamdiner | | align="center" | Amsterdamdiner | ||
|- | |- | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
| Jet Gisolf | | Jet Gisolf | ||
| Roche | | Roche | ||
- | | | + | | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Merck | | Merck | ||
- | | | + | | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Gilead | | Gilead | ||
- | | | + | | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | align="center" | x | + | | align="center" | x |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Shering Plough | | Shering Plough | ||
- | | | + | | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Abbott | | Abbott | ||
- | | | + | | <br> |
- | | | + | | <br> |
| align="center" | x | | align="center" | x | ||
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
- | | | + | | <br> |
|- | |- | ||
| Gerrit Schreij | | Gerrit Schreij | ||
| Viiv Healthcare | | Viiv Healthcare | ||
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
| align="center" | x | | align="center" | x | ||
- | | align="center" | x | + | | align="center" | x |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Gilead | | Gilead | ||
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
| align="center" | x | | align="center" | x | ||
- | | align="center" | x | + | | align="center" | x |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
- | | Johnson en Johnson<br> | + | | Johnson en Johnson<br> |
- | | align="center" | x | + | | align="center" | x |
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
- | | | + | | <br> |
|- | |- | ||
- | | | + | | <br> |
| Boehringer-Ingelheim | | Boehringer-Ingelheim | ||
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
| Redactioneel werk | | Redactioneel werk | ||
|- | |- | ||
- | | | + | | <br> |
| MSD | | MSD | ||
- | | align="center" | | + | | align="center" | <br> |
- | | align="center" | | + | | align="center" | <br> |
| align="center" | x | | align="center" | x | ||
- | | align="center" | | + | | align="center" | <br> |
- | | | + | | <br> |
|} | |} | ||
- | Door de werkgroepleden opgegeven relaties in de periode | + | Door de werkgroepleden opgegeven relaties in de periode 2007-2011. <br> |
<br> | <br> | ||
====== [[Geschiedenis per pagina van deze richtlijn|''De historie van deze pagina vindt u hier.'']] ====== | ====== [[Geschiedenis per pagina van deze richtlijn|''De historie van deze pagina vindt u hier.'']] ====== |
Versie op 9 dec 2011 12:22
Naam | Firma |
Consultatie/ advisering |
Wetenschappelijk onderzoek |
Congres/ andere reis | Cursus | Anders, namelijk |
Kees Brinkman | Viiv | x | | x | x | |
| BMS | x | | | | |
| MSD | x | | x | | |
| Gilead | x | | x | x | |
| Roche | | | x | | |
| Abbott | x | | x | | |
| Jansen-Tibotec | x | | x | x | |
| | | | | | |
Mariska Tuut | Geen | | | | | |
| | | | | | |
Suzanne Geerlings | MSD | x | | x | | |
| Viiv | x | | | | |
| BMS | x | | x | | |
| Gilead | x | | x | x | Amsterdamdiner |
| Abbott | | | x | | |
| Jansen Cilag (Tibotec) | | | x | | |
| Boehringer Ingelheim | | | | | Amsterdamdiner |
| | | | | | |
Jet Gisolf | Roche | | | x | | |
| Merck | | | x | | |
| Gilead | | | x | x | |
| Shering Plough | | | x | | |
| Abbott | | | x | | |
| | | | | | |
Gerrit Schreij | Viiv Healthcare | | | x | x | |
| Gilead | | | x | x | |
| Johnson en Johnson | x | | | | |
| Boehringer-Ingelheim | | | | | Redactioneel werk |
| MSD | | | x | | |
Door de werkgroepleden opgegeven relaties in de periode 2007-2011.